These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 9252706)

  • 21. [Clinical evaluation of tumor markers in patients with colorectal cancer].
    Naritaka Y; Ogawa K; Matsumoto N; Hosokawa T; Kikuchi T; Koyama N; Haga S; Kajiwara T; Sakakibara N
    Gan No Rinsho; 1987 Aug; 33(10):1274-80. PubMed ID: 2444727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Tumor markers in patients with head-neck carcinomas].
    Walther EK; Dahlmann N; Gorgulla HT
    Laryngorhinootologie; 1990 May; 69(5):271-4. PubMed ID: 2354022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease.
    Engarås B; Kewenter J; Nilsson O; Wedel H; Hafström L
    Eur J Surg Oncol; 2001 Feb; 27(1):43-8. PubMed ID: 11237491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
    Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
    J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significance of CA72.4 in patients with colorectal cancer. Comparison with CEA and CA19.9.
    Filella X; Molina R; Mengual PJ; Jo J; Ballesta AM
    J Nucl Biol Med (1991); 1991; 35(3):158-61. PubMed ID: 1816871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical evaluation of a combination assay of CEA, CA-19-9 and TPA in patients with colorectal cancer].
    Nishida O; Shiroto H; Satoh N; Nakajima Y; Manabe K; Kondoh Y; Sano F; Uchino J
    Gan No Rinsho; 1988 Aug; 34(9):1096-100. PubMed ID: 3172515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The monitoring of gynecological radiotherapy using serial tumor marker determinations].
    Wagner RK; Atzinger A; Breit A
    Strahlenther Onkol; 1990 Jul; 166(7):446-52. PubMed ID: 2200151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix.
    Juang CM; Wang PH; Yen MS; Lai CR; Ng HT; Yuan CC
    Gynecol Oncol; 2000 Jan; 76(1):103-6. PubMed ID: 10620449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor markers in patients with relapse of colorectal carcinoma.
    Lipská L; Visokai V; Levý M; Svobodová S; Kormunda S; Fínek J
    Anticancer Res; 2007; 27(4A):1901-5. PubMed ID: 17649792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical evaluation of four tumor markers (CEA, TPA, CA50 and CA72-4) in colorectal cancer].
    Koizumi F; Odagiri H; Fujimoto H; Kawamura T; Ishimori A
    Rinsho Byori; 1992 May; 40(5):523-8. PubMed ID: 1507478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CEA, TPA, CA 19-9, SCC and CYFRA at diagnosis and in the follow-up of anal canal tumors.
    Indinnimeo M; Reale MG; Cicchini C; Stazi A; Fiori E; Izzo P
    Int Surg; 1997; 82(3):275-9. PubMed ID: 9372374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients.
    Nakagoe T; Sawai T; Tsuji T; Jibiki MA; Nanashima A; Yamaguchi H; Yasutake T; Ayabe H; Arisawa K
    Hepatogastroenterology; 2003; 50(51):696-9. PubMed ID: 12828063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Tumor markers in gastrointestinal cancer and its clinical significance].
    Taguchi T; Ota J; Sumida S; Rii M
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):3004-9. PubMed ID: 3479051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Expression of tumor-associated antigen LEA and its significance for pathological diagnosis].
    Feng H; Song JD
    Ai Zheng; 2002 Jun; 21(6):658-62. PubMed ID: 12452070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative analysis of the serum levels of NCC-ST-439, CEA and CA19-9 in patients with colorectal carcinoma.
    Iemura K; Moriya Y
    Eur J Surg Oncol; 1993 Oct; 19(5):439-42. PubMed ID: 8405479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum tumour markers in patients with chronic kidney disease.
    Xiaofang Y; Yue Z; Xialian X; Zhibin Y
    Scand J Clin Lab Invest; 2007; 67(6):661-7. PubMed ID: 17852811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum tumor markers.
    Perkins GL; Slater ED; Sanders GK; Prichard JG
    Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer.
    Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Wang HS; Chen PM
    Hepatogastroenterology; 2002; 49(43):160-4. PubMed ID: 11941943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical evaluation of serum and immunohistochemical expression of SCC and CA19-9 in radiation therapy for cervical cancer.
    Abe A; Nakano T; Morita S; Oka K
    Anticancer Res; 1999; 19(1B):829-36. PubMed ID: 10216501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.